Holen Sie sich die Stockscreener-App
20.66
4.92%
-1.07
Handel nachbörslich:
21.75
1.09
+5.28%
Schlusskurs vom Vortag:
$21.73
Offen:
$21.42
24-Stunden-Volumen:
647.07K
Relative Volume:
0.93
Marktkapitalisierung:
$561.01M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-17.81
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
+9.02%
1M Leistung:
+14.46%
6M Leistung:
+96.20%
1J Leistung:
+0.29%
1-Tages-Spanne:
$20.40
$22.13
1-Wochen-Bereich:
$18.73
$22.40
52-Wochen-Spanne:
$8.04
$23.59
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
20.66 | 590.07M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Technical analysis overview for Arcturus Therapeutics Holdings Inc. stockVolume Spike & Free Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Arcturus Therapeutics Holdings Inc.Gap Up & Smart Allocation Stock Tips - newser.com
Is Arcturus Therapeutics Holdings Inc. stock cheap at current valuation2025 Price Action Summary & Detailed Earnings Play Alerts - newser.com
What technical models suggest about Arcturus Therapeutics Holdings Inc.’s comebackDollar Strength & Short-Term Trading Alerts - newser.com
What dividend safety score for Arcturus Therapeutics Holdings Inc. stockTrend Reversal & High Conviction Trade Alerts - newser.com
How currency fluctuations impact Arcturus Therapeutics Holdings Inc. stockBuy Signal & Accurate Entry and Exit Point Alerts - newser.com
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? - sharewise.com
Arcturus Therapeutics (ARCT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Real time social sentiment graph for Arcturus Therapeutics Holdings Inc.July 2025 Breakouts & Expert Verified Stock Movement Alerts - newser.com
Using data models to predict Arcturus Therapeutics Holdings Inc. stock movement - newser.com
Published on: 2025-10-13 07:05:21 - newser.com
Arcturus Therapeutics Holdings Inc. stock chart pattern explainedQuarterly Profit Review & Long-Term Capital Growth Strategies - newser.com
What MACD and RSI say about Arcturus Therapeutics Holdings Inc.Fed Meeting & Weekly Momentum Picks - newser.com
Arcturus Therapeutics (ARCT) Anticipated to Benefit from Upcomin - GuruFocus
Published on: 2025-10-10 03:52:17 - newser.com
Applying chart zones and confluence areas to Arcturus Therapeutics Holdings Inc.2025 Market Overview & Verified High Yield Trade Plans - newser.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
How to use Fibonacci retracement on Arcturus Therapeutics Holdings Inc.Quarterly Performance Summary & Technical Pattern Based Signals - newser.com
Is this a good reentry point in Arcturus Therapeutics Holdings Inc.July 2025 Selloffs & Free High Return Stock Watch Alerts - newser.com
Arcturus Stock Rockets From $9 To $18 In 5 MonthsAll Eyes On Upcoming Cystic Fibrosis Data - RTTNews
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech Gem with 225% Potential Upside - DirectorsTalk Interviews
Published on: 2025-10-09 02:58:21 - newser.com
Is Arcturus Therapeutics Holdings Inc a good long term investmentChart Pattern Recognition & Double Or Triple Investment - earlytimes.in
Arcturus Therapeutics Holdings Inc Stock Analysis and ForecastBollinger Bands Signals & Investor Community Interactions - earlytimes.in
Public Employees Retirement System of Ohio Makes New Investment in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 4.7%Should You Sell? - MarketBeat
What high frequency data says about Arcturus Therapeutics Holdings Inc.Quarterly Risk Review & Weekly Top Gainers Alerts - newser.com
Does Arcturus Therapeutics Holdings Inc. fit your quant trading modelTrade Risk Summary & Long-Term Capital Growth Ideas - newser.com
Arcturus Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Best data tools to analyze Arcturus Therapeutics Holdings Inc. stockJuly 2025 Summary & Verified Technical Signals - newser.com
Arcturus Therapeutics Holdings (ARCT): An Investor's Insight Into A Potential 236% Upside - DirectorsTalk Interviews
Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap UpHere's What Happened - MarketBeat
High Growth Tech Stocks In The US For September 2025 - simplywall.st
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):